Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Registry

被引：0
|
作者：
George, Tracy I. [1 ,2 ]
Cogle, Christopher R. [3 ]
Garcia-Manero, Guillermo [4 ]
Grinblatt, David L. [5 ]
Komrokji, Rami [6 ]
Savona, Michael R. [7 ,8 ]
Scott, Bart L. [9 ]
Sekeres, Mikkael A. [10 ]
Steensma, David P. [11 ]
Flick, E. Dawn [12 ]
Kiselev, Pavel [13 ]
Louis, Chrystal U. [13 ]
Nifenecker, Melissa [13 ]
Swern, Arlene S. [13 ]
Foucar, Kathryn [14 ]
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] ARUP Labs, Salt Lake City, UT USA
[3] Univ Florida, Med, Gainesville, FL USA
[4] MD Anderson Canc Ctr, Houston, TX USA
[5] NorthShore Univ HealthSyst, Evanston, IL USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[7] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
[8] Vanderbilt Univ, Med Ctr, Program Canc Biol, Nashville, TN USA
[9] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[10] Cleveland Clin, Cleveland, OH 44106 USA
[11] Dana Farber Canc Inst, Boston, MA 02115 USA
[12] Celgene Corp, San Francisco, CA USA
[13] Celgene Corp, Summit, NJ USA
[14] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122913
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4747
引用
收藏
页数：4
相关论文
共 40 条
  • [31] Adaptive randomization of idarubicin and Ara-C (IA) ± interleukin (IL11) in patients with newly diagnosed (ND) acute Myelogenous leukemia (AML) or high-risk Myelodysplastic syndrome (MDS)
    Tsimberidou, AM
    Estey, E
    Cortes, J
    Thomas, D
    Garcia-Manero, G
    Faderl, S
    Verstovsek, S
    O'Brien, S
    Kantarjian, R
    Giles, F
    BLOOD, 2002, 100 (11) : 264B - 264B
  • [32] Phase II Study of 5-Azacitidine and Vorinostat In Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance or Presence of Other comorbidities
    Garcia-Manero, Guillermo
    Estey, Elihu H.
    Jabbour, Elias
    Kadia, Tapan
    Estrov, Zeev
    Cortes, Jorge
    Boone, Patricia Ann
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 266 - 266
  • [33] Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
    Tomlinson, Benjamin
    de Lima, Marcos
    Cogle, Christopher R.
    Thompson, Michael A.
    Grinblatt, David L.
    Pollyea, Daniel A.
    Komrokji, Rami S.
    Roboz, Gail J.
    Savona, Michael R.
    Sekeres, Mikkael A.
    Abedi, Mehrdad
    Garcia-Manero, Guillermo
    Kurtin, Sandra E.
    Maciejewski, Jaroslaw P.
    Patel, Jay L.
    Revicki, Dennis A.
    George, Tracy I.
    Flick, E. Dawn
    Kiselev, Pavel
    Louis, Chrystal U.
    Degutis, Irene S.
    Nifenecker, Melissa
    Erba, Harry P.
    Steensma, David P.
    Scott, Bart L.
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (07): : 460e1 - 460e9
  • [34] A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
    Swaminathan, Mahesh
    Dinardo, Courtney Denton
    Maiti, Abhishek
    Pemmaraju, Naveen
    Ohanian, Maro
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Short, Nicholas James
    Wierda, William G.
    Jain, Nitin
    Kornblau, Steven Mitchell
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Farnesyl transferase inhibitor (tipifarnib, zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-c) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Verstovsek, S
    Estrov, Z
    Giles, F
    Ravandi, F
    Wright, J
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 784A - 784A
  • [36] Farnesyl transferase inhibitor (Tipifarnib, zarnestra; z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabime (ara-C) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Alvarez, Ricardo H.
    Kantarijan, Hagop
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi-Kashani, Farhad
    Verstovsek, Srdan
    Giles, Francis
    O'Brien, Susan
    Koller, Charles Asa
    Faderl, Stefan
    Thomas, Deborah
    Wright, John J.
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 565A - 566A
  • [37] Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities
    Garcia-Manero, Guillermo
    Estey, Elihu H.
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Naqvi, Kiran
    Levine, Ross L.
    Estrov, Zeev
    Quintas-Cardama, Alfonso
    Konopleva, Marina
    Faderl, Stefan
    Tanaka, Maria
    Yang, Hui
    Ravandi, Farhad
    Wierda, William G.
    Cortes, Jorge E.
    Boone, Patricia Ann
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 279 - 279
  • [38] A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States
    Byrd, John C.
    Gatz, Jennifer L.
    Cripe, Larry D.
    Louis, Cynthia Lim
    Mims, Alice S.
    Borate, Uma
    Yocum, Ashley O.
    Gana, Theophilus
    Burd, Amy
    BLOOD, 2021, 138
  • [39] Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
    Garcia-Manero, Guillermo
    Wei, Andrew H.
    Porkka, Kimmo
    Knapper, Steve
    Traer, Elie
    Scholl, Sebastian
    Vey, Norbert
    Wermke, Martin
    Janssen, Jeroen
    Narayan, Rupa
    Loo, Sun
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Orlando, Elena
    Patel, Nidhi
    Makofske, Jessica
    Ma, Fei
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael L.
    Borate, Uma
    Brunner, Andrew M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S350 - S350
  • [40] Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
    Zeidan, Amer M.
    Cavenagh, James
    Voso, Maria Teresa
    Taussig, David
    Tormo, Mar
    Boss, Isaac
    Copeland, Wilbert B.
    Gray, Vanessa E.
    Previtali, Alessandro
    O'Connor, Tim
    Rose, Shelonitda
    Beach, C. L.
    Silverman, Lewis R.
    BLOOD, 2019, 134
1234